NR3C1 and Parkinson disease: Molecular docking verified that ESR1, MAOA, NR3C1, VEGFA, and mTOR have high affinities for the main active ingredients of BZD, diosgenin, isopimaric acid, stigmasterol, and beta-sitosterol, providing data support for BZD as a potential drug for the treatment of PD; however, further experimental studies are needed to confirm its effectiveness.